Huhle 1999.

Methods	4‐week dietary placebo run‐in period 8‐week randomised, double‐blind, placebo‐controlled trial
Participants	22 men and women age 30‐70 years serum LDL‐C > 160 mg/dL (4.14 mmol/L) serum TG < 300 mg/dL (3.39 mmol/L) exclusion criteria: type 1 diabetes mellitus, pregnancy severe liver and/or pancreatic disease renal failure, MI within 2 months of trial, heart failure, uncontrolled hypertension and medications that affect lipids within 3 weeks of trial
Interventions	Placebo 0‐8 weeks Fluvastatin 40 mg twice daily for 0‐8 weeks
Outcomes	per cent change from baseline at 8 weeks of serum TC, LDL‐C, HDL‐C, and triglycerides
Source of Funding	unknown
Notes	WDAEs were not reported SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random sequence generation method not reported
Allocation concealment (selection bias)	Unclear risk	Aallocation concealment not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind treatment placebo and fluvastatin capsule appearances were not reported as appearing identical Lipid parameter measurements unlikely influenced by lack of proper blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	WDAEs were not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	9% participants were not included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported